The NPPA has set ceiling prices for 355 drugs, 882 formulations: Mandaviya
The National Pharmaceutical Pricing Authority (NPPA) has set ceiling prices for 355 drugs and 882 formulations as part of the 2015 national essential drugs list, Parliament informed on Tuesday.
“Most of the drugs that are part of the COVID-19 management protocol have ceiling prices, namely paracetamol, dexamethasone, methylprednisolone, IVIG, enoxaparin, budesonide, heparin and amphotericin, etc, “Chemicals and Fertilizers Minister Mansukh Mandaviya said in a statement. written answer to a question in the Lok Sabha.
In the case of a few unscheduled drugs like remdesivir, which are part of the COVID-19 protocol and are unscheduled, upon government intervention, the MRPs of various brands of remdesivir have been voluntarily reduced by major manufacturers / marketers of the drug. injection of remdesivir. (freeze-dried), he added.
Maximum inter-brand retail prices (MRP) which ranged up to Rs 5,400 per vial have been reduced to less than Rs 3,500, the minister said.
In addition, to facilitate availability and ensure an affordable price, the NPPA capped the profit margin for oxygen concentrators at 70% on the distributor-level price video notification dated June 3, 2021 and on the oximeter. monitor, glucometer, blood pressure monitor, nebulizer and digital thermometer. video notification dated July 13, 2021, “he added.
In addition, the retail prices of 1,640 formulations have been set under the DPCO, 2013, to date and in recent years, exercising extraordinary powers under the DPCO, 2013, in the public interest. The NPPA had set the ceiling price for stents in February 2017, the ceiling price for knee implants in August 2017, and also capped the profit margin on a selection of 42 cancer drugs in February 2019, Mandaviya said.
(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)